mCyp c 1

Developed for: food allergy
Investigated by: Odense University Hospital · George Stavroulakis · Hospital Regional de Malaga · Hospital San Carlos, Madrid · Hospital Universitario Reina Sofia de Cordoba · Landspitali University Hospital
+6 more
· Medical University of Lodz · National University Hospital NUHD Denmark · National and Kapodistrian University of Athens · Rigshospitalet, Denmark · UMC Utrecht · University Hospital, Gentofte, Copenhagen

today NCT02382718 · Ph 2 NCT02017626 · Ph 1/2

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT02017626	Aug 2013 → Oct 2014	—	Rigshospitalet, Denmark	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT02382718	Oct 2015 → Feb 2017	food allergy	George Stavroulakis	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	mCyp c 1	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02382718 ↗ 1 NCT02017626 ↗
Modality	Protein / enzyme biologic	“modified recombinant fish parvalbumin” NCT02017626 ↗
Route	Subcutaneous	“Subcutaneous Immunotherapy treatment (SCIT)” NCT02017626 ↗